Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets

British Journal of Clinical Pharmacology

Volumn 44, Issue 1, 1997, Pages 77-84

  Osamah, Hussein ^b   Mira, Rosenblat ^b   Sorina, Schlezinger ^b   Shlomo, Keidar ^b   Michael, Aviram ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Fluvastatin; Hypercholesterolaemia; Lovastatin; Platelet aggregation; Pravastatin

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE LIPID; MEVINOLIN; PHOSPHOLIPID; PRAVASTATIN; RADIOISOTOPE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BINDING COMPETITION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG BINDING SITE; DRUG MECHANISM; HUMAN; HUMAN CELL; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; LIPID COMPOSITION; LIPOPHILICITY; MALE; MEMBRANE FLUIDITY; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; URTICARIA;

EID: 0030832526     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00625.x     Document Type: Article

References (43)

1. Aviram M. Effect of lipoproteins and platelets on macrophage cholesterol metabolism. In Blood Cell Biochemistry ed Harris JR, New York, Plenum Publishing 1992; 2: 179-207.
2. Surya II, Akkerman JW. The influence of lipoproteins on blood platelets. Am Heart J 1993; 125: 272-275.
3. Ross R. The pathogenesis of atherosclerosis: an update. New Engl J Med 1986; 314: 488-500.
4. Goldstein JL, Brown MS. The low density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Biochem 1977; 46: 897-930.
5. Aviram M. Platelets and the arterial wall lesion. Curr Opin Lipidol 1992; 3: 344-348.
6. Sizinger H. Role of platelets in atherosclerosis. Sem Thromb Haemost 1986; 12: 124-133.
7. Packham KA, Mustard JF. The role of platelets in the development and complications of atherosclerosis. Semin Hematol 1986; 23: 8-26.
8. Folkman J, Klagsburn M. Angiogenic factors. Science 1987; 234: 442-447.
9. Chait A, Ross R, Albers JJ, Bierman EL. Platelet-derived growth factor stimulates activity of low density lipoprotein receptors. Proc Natl Acad Sci U.S.A. 1980; 77: 4084-4088.
10. Curtiss LK, Black AS, Takagi Y, Plow EF. New mechanism for foam cell generation in atherosclerotic lesions. J Clin Invest 1987; 80: 367-373.
11. Mendelsohn ME, Loscalzo J. Role of platelets in cholesteryl ester formation by U-937 cells. J Clin Invest 1988; 81: 62-68.
12. Fuhrman B, Brook JG, Aviram M. Activated platelets secrete a protein like factor that stimulates oxidized-LDL receptor activity in macrophages. J Lipid Res 1991; 32: 1113-1123.
13. Aviram M. Platelet secretory products enhance LDL receptor activity and inhibit scavenger receptor activity in human monocyte derived macrophages. Metabolism 1989; 38: 425-430.
14. Hayashi T, Naito M, Kuzuya M, et al. Role of platelet secretory products in modified lipoprotein metabolism in macrophages. Artery 1989; 16: 248-262.
15. Aviram M, Brook JG. Platelet interaction with high and low density lipoproteins. Atherosclerosis 1983; 46: 259-268.
16. Aviram M. LDL-platelet interaction under oxidative stress induced macrophage foam cell formation. Thrombosis and Haemostasis 1995; 74: 560-564.
17. Aviram M, Brook JG. The effect of human plasma on platelet function in familial hypercholesterolaemia. Thromb Res 1982; 26: 101-109.
18. Viener A, Brook JG, Aviram M. Abnormal plasma lipoprotein composition in hypercholesterolaemic patients induces platelet activation. Eur J Clin Invest 1984; 14: 207-213.
19. Sirtori CR, Colli S. Influence of lipid-modifying agents on hemostasis. Cardiovasc Drugs Ther 1993; 7: 817-823.
20. Miller GJ. Lipoproteins and thrombosis: effects of lipid lowering. Curr Opin Lipidol 1995; 6: 38-42.
21. Brook JG, Winterstein G, Aviram M. Platelet function and lipoprotein levels after plasma exchange in patients with familial hypercholesterolaemia. Clin Sci 1983; 64: 637-642.
22. Kaczmarek D, Hohlfeld T, Wambach G, Schror K. The actions of lovastatin on platelets function and platelet eicosanoid receptors in type II hypercholesterolaemia. A double-bind, placebo-controlled prospective study. Eur J Clin Pharmacol 1993; 45: 451-457.
23. Levy RJ, Troendle AJ, Fattu MA. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993; 87(Suppl 4): 1145-1153.
24. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24-33.
25. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992; 41: 229-235.
26. Keidar S, Aviram M, Maor I, Oiknine J, Brook JG. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages. Br J Clin Pharmacol 1994; 38: 513-519.
27. Aviram M, Keidar S, Brook JG. Dual effect of lovastatin and simvastatin on LDL-macrophage interaction. Eur J Clin Chem Clin Biochem 1991; 29: 657-664.
28. Hochgraf E, Levy Y, Aviram M, Brook JG, Cogan U. Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolaemic patients. Metabolism 1994; 43: 7-11.
29. Aviram M, Rosenblat M, Brook JG. Secretory products from human monocyte-derived macrophages enhance platelet aggregation. Metabolism 1991; 40: 270-274.
30. Chiamori N, Henry RJ. Study of the ferric chloride method for determination of total cholesterol and cholesterol esters. Am J Clin Pathol 1959; 31: 305-309.
31. Rouser G, Fkeischer S, Yamamoto A. Two dimensional thin layer chromatography of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 5: 494-496.
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RS. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.
33. Shastri KM, Carvlho ACA, Lees RS. Platelet function and platelet lipid composition in the dyslipoproteinemias. J Lipid Res 1980; 21: 467-478.
34. Ardlie NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoprotein. Atherosclerosis 1989; 76: 117-124.
35. Shmulewitz A, Brook JG, Aviram M. Native and modified low-density lipoprotein interactions with human platelets in normal and homozygous familial hypercholesterolaemic subjects. Biochem J 1984; 224: 13-20.
36. Hassal DG, Bruckdorfer KR. Platelet low density lipoprotein receptors. Biochem Soc Trans 1985; 13: 1189-1190.
37. Gasser JA, Cooper MB, Tan KCB, Saggerson ED, Betteridge DJ. Decreased sensitivity to adenosine in platelets from patients with familial hypercholesterolaemia - a change reversed by cholestyramine treatment. Eur J Clin Invest 1993; 23: 803-811.
38. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-3177.
39. Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992; 32: 630-638.
40. Pan HY, DeVault AR, Wang-Inverson D, Ivashkiv E, Swanson BN, Sugerman A. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990; 30: 1128-1135.
41. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994; 73: 3D-11D.
42. Barrow SE, Stratton PD, Benjamin N, Brassfield T, Ritter JM. Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolaemia at risk of coronary heart disease. Br J Clin Pharmacol 1991; 32: 127-129.
43. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of LDL to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolaemic effect of the drug and its binding to the LDL. Atherosclerosis 1997; 128: 11-18.